pbf-680
Small moleculeexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01845181)
Timeline
Indications
Mechanism of action
- Adenosine A1 receptorANTAGONIST
ADORA1 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545162 ↗
Also known as
- pbf-680
- pbf-680
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05262218 | Phase 2 | Dec 20, 2021 | Paloma Pharmaceuticals, Inc., SCOPE International AG |
| NCT03774290 | Phase 2 | Jun 1, 2018 | Paloma Pharmaceuticals, Inc., Pivotal S.L. |
| NCT02635945 | Phase 2 | Apr 1, 2016 | Hospital de Sant Pau i Santa Tecla de Tarragona, Paloma Pharmaceuticals, Inc., University of Barcelona |
| NCT02208973 | Phase 1 | May 1, 2014 | CIM Sant Pau, Palo Biofarma, S.L, University of Barcelona |
| NCT01939587 | Phase 2 | Dec 1, 2013 | Palo Biofarma, S.L, University of Barcelona |
| NCT01845181 | Phase 1 | Apr 1, 2013 | Palo Biofarma, S.L, University of Barcelona |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Barcelona | Academic/Hospital | 4 | 3 | 2 | 2013 |
| Palo Biofarma, S.L | For profit | 3 | 0 | 2 | 2013 |
| Paloma Pharmaceuticals, Inc. | For profit | 3 | 3 | 1 | 2016 |
| CIM Sant Pau | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Hospital de Sant Pau i Santa Tecla de Tarragona | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Pivotal S.L. | For profit | 1 | 0 | 1 | 2018 |
| SCOPE International AG | For profit | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1